Abstract
A recent study reported that routinely screening for sarcopenia and nutritional status was helpful in determining toxicity and treatment in patients with non-small cell lung cancer. Although a decrease in muscle mass was detected in 68.8% of the participants, it is not evident what proportion the patients had true sarcopenia. Clarification of these issues may be relevant to the study results.